DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Peeters M, Price T, Hotko Y. et al.
Randomized phase III study of panitumumab with FOLFIRI vs. FOLFIRI alone as second line treatment (tx) in patients (pts) with metastatic colorectal cancer.
Eur J Cancer 2009; 7: 10 (Abstr 14LBA)-
We do not assume any responsibility for the contents of the web pages of other providers.